NT-proBNP, C-Reactive Protein and Soluble uPAR in a Bi-Ethnic Male Population: The SAfrEIC Study

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Kruger, Ruan ^a   Schutte, Rudolph ^a   Huisman, Hugo W ^a   Hindersson, Peter ^b   Olsen, Michael H ^a,c   Eugen Olsen, Jesper ^d   Schutte, Aletta E ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

^b NORTH DENMARK REGIONAL HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; UROKINASE RECEPTOR;

ADULT; ARTICLE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ETHNIC DIFFERENCE; HIGH RISK POPULATION; HUMAN; MALE; NEGRO; PROTEIN DETERMINATION; SOUTH AFRICA;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INFLAMMATION; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REGRESSION ANALYSIS; SOLUBILITY; SOUTH AFRICA;

EID: 84874859541     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058506     Document Type: Article

References (35)

1. Kengne AP, Anderson CS, (2006) The neglected burden of stroke in Sub-Saharan Africa. Int J Stroke 1 (4):: 180-190.
2. Fourie CMT, Van Rooyen JM, Kruger A, Olsen MH, Eugen-Olsen J, et al. (2012) Soluble urokinase plasminogen activator receptor (suPAR) is associated with metabolic changes in HIV-1-infected Africans: a prospective study. Inflammation 35 (1):: 221-229.
3. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, et al. (2000) Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 35: 1628-1637.
4. Yu H, Rifai N, (2000) High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy. Clin Biochem 33: 601-610.
5. Ridker PM, Stampfer MJ, Rifai N, (2001) Novel risk factors for systemic atherosclerosis. JAMA 285: 2481-2485.
6. Meigs JB, Hu FB, Rifai N, Manson JAE, (2004) Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 291: 1978-1986.
7. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen T, et al. (2010) Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 268: 296-308.
8. Sehestedt T, Lyngbæk S, Eugen-Olsen J, Jeppesen J, Andersen O, et al. (2011) Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis 216: 237-243.
9. Nielsen SE, Schjoedt KJ, Rossing K, Persson F, Schalkwijk CG, et al. (2012) Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. J RAAS doi:10.1177/1470320312460290.
10. McCullough PA, Sandberg KR, (2003) B-type natriuretic peptide and renal disease. Heart Fail Rev 8: 355-358.
11. Jensen J, Ma L, Fu MLX, Svaninger D, Lundberg P, et al. (2010) Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio. Clin Res Cardiol 99: 445-452.
12. O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, et al. (2005) Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 23: 697-701.
13. Imholz BPM, Wieling W, Van Montfrans GA, Wesseling KH, (1998) Fifteen years' experience with finger arterial pressure monitoring. Cardiovasc Res 38: 605-616.
14. Guelen I, Westerhof BE, Van der Sar GL, Van Montfrans GA, Kiemeneij F, et al. (2008) Validation of brachial artery pressure reconstruction from finger arterial pressure. J Hypertens 26: 1321-1327.
15. Marfell-Jones M, Olds T, Stewart A, Carter L (2006) International standards for anthropometric assessment. ISAK: Potchefstroom, South Africa; 32-89 p.
16. Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, et al. (2003) The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes 27: 443-449.
17. Ossowski L, Aguirre-Ghiso JA, (2000) Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 12: 613-620.
18. Morrow DA, Braunwald E, (2003) Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 108: 250-252.
19. Pepys BM, (1983) Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 34: 141-212.
20. Thunø M, Macho B, Eugen-Olsen J, (2009) suPAR: the molecular crystal ball. Dis Markers 27: 157-172.
21. McDade TW, (2003) Life history theory and the immune system: steps toward a human ecological immunology. Am J Phys Anthropol 122 (37):: 100-125.
22. Crimmins EM, Finch CE, (2006) Infection, inflammation, height, and longevity. Proc Natl Acad Sci USA 103: 498-503.
23. Hansson GK, Libby P, (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6: 508-519.
24. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, et al. (2009) ACCF/AHA Practice Guideline: Focused Update. Circulation 119: 1977-2016.
25. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, et al. (2003) From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 108: 1664-1672.
26. Opie LH, Seedat YK, (2005) Hypertension in sub-Saharan African populations. Circulation 112: 3562-3568.
27. Must A, Spadano J, Coakley EH, Field AE, Colditz G, et al. (1999) The disease burden associated with overweight and obesity. JAMA 282: 1523-1529.
28. Raizada V, Thakore K, Luo W, McGuire P, (2001) Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension. Mol Cell Biochem 216: 137-140.
29. Uusimaa P, Tokola H, Ylitalo A, Vuolteenaho O, Ruskoaho H, et al. (2004) Plasma B-type natriuretic peptide reflects left ventricular hypertrophy and diastolic function in hypertension. Int J Cardiol 97: 251-256.
30. Hall C, (2005) NT-ProBNP: the mechanism behind the marker. J Card Fail 11: S81-83.
31. Binder BM, Mihaly J, Prager GW, (2007) uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haem 97: 336-342.
32. Prager GW, Breuss JM, Steurer S, Mihaly J, Binder BR, (2004) Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood 103: 955-962.
33. Sackner-Bernstein JD, (2000) The myocardial matrix and the development and progression of ventricular remodeling. Curr Cardiol Rep 2: 112-119.
34. Yap LB, (2004) B-type natriuretic peptide and the right heart. Heart Fail Rev 9: 99-105.
35. Pemberton CJ, Johnson ML, Yandle TG, Espiner EA, (2000) Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 36: 355-359.